Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TAP Spectracef

Executive Summary

NDA for the cephalosporin antibiotic cefditoren pivoxil submitted Dec. 28 for acute exacerbations of chronic bronchitis, sinusitis, pharyngitis and skin structure infections in adults and adolescents. TAP is also conducting pediatric studies of Spectracef and plans to file for pediatric indications in the future

You may also be interested in...



TAP Spectracef Launch Planned For Early 2001; Prevacid Sales Are $735 Mil.

Abbott is predicting an early 2001 launch for TAP's cephalosporin antibiotic Spectracef, currently under review at FDA.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel